Setterwalls has advised EQL Pharma in connection with oversubscribed rights issue

EQL Pharma has carried out a rights issue of shares which was oversubscribed to 161.7 %. Through the rights issue, EQL Pharma will receive gross proceeds of approximately MSEK 25.

EQL Pharma is specialized in developing and selling niche generics, generics with little or no competition except the original medicine, on the Nordic market. EQL Pharma also conducts an extensive development work in cooperation with leading contract manufacturers and major pharmaceutical companies in inter alia India and China.